The Transverse myelitis treatment market expected to develop at a CAGR of 3.2 % over the prediction period. According to the Department of Neurology at the University of Columbia, this condition occurs most commonly in children aged 10 to 19 years and in adults aged 30 to 39 years.
Transverse myelitis signs and symptoms include discomfort, arms or leg weakness, irregular feelings, and bladder & bowel problems. Patients with transverse myelitis experience either coldness or burning, numbness and tingling. The precise explanation for transverse myelitis is not clear.
The improvement in government prioritization of genetic disorder drugs is also projected to improve the world market in the near future. Furthermore, the shortage of health care experts in Latin America and Middle East & Africa hinders the growth of regional demand for transverse myelitis treatments. Nonetheless, heightened government funding for diagnostic procedures is likely to boost the demand for transverse myelitis care.
Globally, groups promoting the treatment of this condition are the Information Centre on Genetic and Rare Diseases (GARD), the NIH / National Institute for Neurological Disorders and Stroke, the Spinal Cord Injury Professionals Academy, Inc., and the Transverse Myelitis Association.
Report : Transverse Myelitis Treatment Market - By Diagnosis (Magnetic Resonance Imaging (MRI), Lumbar Puncture, Blood Tests, Others), By End-User (Hospitals & Clinics, Diagnostic Centres, Others), and By Region (North America, Asia Pacific, Europe, Middle East & Africa and Latin America) - Industry Analysis, opportunity and Forecast 2020 To 2027